MetaVia Appoints Dr. Sarah Kaplan Browne as Chief Medical Officer

MetaVia Inc. announced the appointment of Sarah Kaplan Browne, M.D., as its new Chief Medical Officer, effective October 12, 2026. Dr. Browne's extensive experience in liver and metabolic disease drug development is expected to be crucial as the company advances its key clinical programs.

Key Details

• Appointment: Sarah Kaplan Browne, M.D. named Chief Medical Officer, effective October 12, 2026.
• Relevant Experience: Dr. Browne has over 20 years of experience, including leading the development of therapies for MASH (metabolic dysfunction-associated steatohepatitis) and dual GLP-1/glucagon receptor agonists, such as pemvidutide.
• Strategic Timing: The appointment comes as MetaVia prepares for the anticipated Q4 2026 topline data from its Phase 1 trial of DA-1726, a key cardiometabolic drug candidate. Dr. Browne will help guide the next development stages for DA-1726 and vanoglipel (for MASH).